Opendata, web and dolomites

CTS-TEs-ADprogress SIGNED

Cell type-specific molecular analysis of epigenetic changes and transposable element derepression in Alzheimer's disease progression

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CTS-TEs-ADprogress project word cloud

Explore the words cloud of the CTS-TEs-ADprogress project. It provides you a very rough idea of what is the project "CTS-TEs-ADprogress" about.

thereby    age    limitations    molecular    gene    plays    chromatin    influencing    signals    ps1    population    bulk    occurred    neurodegeneration    model    dysregulation    hippocampal    once    imperative    death    aging    heterochromatin    patients    survival    burden    memory    translating    resolution    plaques    isolated    environmental    symptom    linked    disease    diagnosed    shown    impairment    seq    correlating    te    epigenome    atac    beta    chronic    regulatory    point    samples    critical    suggesting    recapitulates    few    subtypes    epigenetic    cell    app    symptoms    mutations    stage    underlying    human    transposition    transposable    cut    onset    drivers    mice    structure    coverage    stress    treatments    mouse    contributor    lack    tissue    evident    rna    decades    progression    mechanisms    worldwide    preclinical    pathological    usually    cellular    either    limited    single    neuronal    expression    inhibit    insertional    run    neuron    pathology    alterations    alzheimer    hallmarks    healthcare    ad   

Project "CTS-TEs-ADprogress" data sheet

The following table provides information about the project.

Coordinator
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV 

Organization address
address: SIGMUND FREUD STRASSE 27
city: BONN
postcode: 53127
website: www.dzne.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 174˙806 €
 EC max contribution 174˙806 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV DE (BONN) coordinator 174˙806.00

Map

 Project objective

Alzheimer’s disease (AD) is a major contributor to disease burden and healthcare costs worldwide. AD is usually diagnosed once symptoms like memory impairment become evident. However, at this point typical AD pathology such as Aβ plaques and cell death is already widespread, suggesting that molecular changes have occurred decades before symptom onset. With an increasingly aging population and no available treatments, it has become imperative to identify the molecular mechanisms underlying onset and progression of AD. Chronic environmental stress and age-associated changes in stress response have been associated as drivers of AD pathology. The epigenome plays a critical role in translating stress signals into a cellular response by influencing gene expression, which can either promote or inhibit cell survival. Several studies have shown that alterations in chromatin structure, including heterochromatin loss, and associated changes in gene expression contribute to neurodegeneration. In addition, neuronal death was also linked to transposable element (TE) dysregulation due to epigenetic changes, which can lead to changes in gene expression and insertional mutations due to transposition. However, our understanding of epigenetic changes at onset and during progression of AD pathology is very limited, as current studies have two major limitations: 1) lack of cell type resolution due to use of bulk tissue samples and 2) coverage of only few or only one disease stage. Here, single-cell RNA-seq and ATAC-seq as well as CUT&RUN on isolated hippocampal neuron subtypes will be used to identify cell type-specific alterations of gene expression and gene regulatory mechanisms during onset and progression of AD pathology in the APP/PS1 mouse model. APP/PS1 mice are a well-established AD model, which recapitulates many characteristics of preclinical AD in human patients and thereby allows correlating the identified changes with the development of specific pathological hallmarks.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CTS-TES-ADPROGRESS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CTS-TES-ADPROGRESS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Widow Spider Mating (2020)

Immature mating as a novel tactic of an invasive widow spider

Read More  

GLORIOUS (2019)

Digital Poetry in Today’s Russia: Canonisation and Translation

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More